Modern Clinical Research on LSD
暂无分享,去创建一个
[1] R. Strassman,et al. Dose-response study of N,N-dimethyltryptamine in humans. I. Neuroendocrine, autonomic, and cardiovascular effects. , 1994, Archives of general psychiatry.
[2] D J Nutt,et al. LSD‐induced entropic brain activity predicts subsequent personality change , 2016, Human brain mapping.
[3] D. E. Nichols,et al. Psychedelics as Medicines: An Emerging New Paradigm , 2017, Clinical pharmacology and therapeutics.
[4] W. Richards,et al. LSD-assisted psychotherapy with terminal cancer patients. , 1969, Current psychiatric therapies.
[5] Matthew W. Johnson,et al. Mystical experiences occasioned by the hallucinogen psilocybin lead to increases in the personality domain of openness , 2011, Journal of psychopharmacology.
[6] C. Grob,et al. Pilot study of psilocybin treatment for anxiety in patients with advanced-stage cancer. , 2011, Archives of general psychiatry.
[7] T. S. Krebs,et al. Over 30 million psychedelic users in the United States , 2013, F1000Research.
[8] A. Halberstadt. Recent advances in the neuropsychopharmacology of serotonergic hallucinogens , 2015, Behavioural Brain Research.
[9] Robert Leech,et al. LSD alters eyes‐closed functional connectivity within the early visual cortex in a retinotopic fashion , 2016, Human brain mapping.
[10] Felix Hasler,et al. Acute psychological and physiological effects of psilocybin in healthy humans : a double-blind , placebo-controlled dose – effect study , 2004 .
[11] Christoph Eisenegger,et al. MDMA enhances emotional empathy and prosocial behavior. , 2014, Social cognitive and affective neuroscience.
[12] Robert Leech,et al. Functional connectivity measures after psilocybin inform a novel hypothesis of early psychosis. , 2013, Schizophrenia bulletin.
[13] R. A. Sewell,et al. Indoleamine Hallucinogens in Cluster Headache: Results of the Clusterbusters Medication Use Survey , 2015, Journal of psychoactive drugs.
[14] M. Liechti,et al. In Vitro Characterization of Psychoactive Substances at Rat, Mouse, and Human Trace Amine-Associated Receptor 1 , 2016, The Journal of Pharmacology and Experimental Therapeutics.
[15] E. Bullmore,et al. Increased Global Functional Connectivity Correlates with LSD-Induced Ego Dissolution , 2016, Current Biology.
[16] R. Mowbray,et al. HALLUCINOGENS , 1970, The Medical journal of Australia.
[17] A. Young,et al. Psychedelics in the treatment of unipolar mood disorders: a systematic review , 2016, Journal of psychopharmacology.
[18] T. S. Krebs,et al. Lysergic acid diethylamide (LSD) for alcoholism: meta-analysis of randomized controlled trials , 2012, Journal of psychopharmacology.
[19] Kevin Murphy,et al. Neural correlates of the LSD experience revealed by multimodal neuroimaging , 2016, Proceedings of the National Academy of Sciences.
[20] Andreas Bäbler,et al. Psilocybin induces schizophrenia‐like psychosis in humans via a serotonin‐2 agonist action , 1998, Neuroreport.
[21] J. Halpern,et al. Do hallucinogens cause residual neuropsychological toxicity? , 1999, Drug and alcohol dependence.
[22] D. Araujo,et al. Antidepressant effects of a single dose of ayahuasca in patients with recurrent depression: a preliminary report. , 2015, Revista brasileira de psiquiatria.
[23] K. Murnane,et al. The behavioral pharmacology of hallucinogens. , 2008, Biochemical pharmacology.
[24] D. Nutt,et al. LSD modulates music-induced imagery via changes in parahippocampal connectivity , 2016, European Neuropsychopharmacology.
[25] F. Vollenweider,et al. Positron Emission Tomography and Fluorodeoxyglucose Studies of Metabolic Hyperfrontality and Psychopathology in the Psilocybin Model of Psychosis , 1997, Neuropsychopharmacology.
[26] P. Anderer,et al. Topographic pharmaco-EEG mapping of the effects of the South American psychoactive beverage ayahuasca in healthy volunteers. , 2002, British journal of clinical pharmacology.
[27] F. Vollenweider,et al. The Effect of 5-HT2A/1a Agonist Treatment On Social Cognition, Empathy, and Social Decision-making , 2015, European psychiatry.
[28] H. Isbell,et al. Comparison of psilocin with psilocybin, mescaline and LSD-25 , 2004, Psychopharmacologia.
[29] M. Liechti,et al. Multifaceted empathy of healthy volunteers after single doses of MDMA: A pooled sample of placebo-controlled studies , 2017, Journal of psychopharmacology.
[30] H. Emrich,et al. The Pharmacology of Lysergic Acid Diethylamide: A Review , 2008, CNS neuroscience & therapeutics.
[31] F. Vollenweider,et al. The Fabric of Meaning and Subjective Effects in LSD-Induced States Depend on Serotonin 2A Receptor Activation , 2017, Current Biology.
[32] R. Strassman,et al. Psilocybin-assisted treatment for alcohol dependence: A proof-of-concept study , 2015, Journal of psychopharmacology.
[33] Karl J. Friston,et al. Broadband Cortical Desynchronization Underlies the Human Psychedelic State , 2013, The Journal of Neuroscience.
[34] Matthew W. Johnson,et al. Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial , 2016, Journal of psychopharmacology.
[35] R. E. Belleville,et al. Studies on lysergic acid diethylamide (LSD-25). I. Effects in former morphine addicts and development of tolerance during chronic intoxication. , 1956, A.M.A. archives of neurology and psychiatry.
[36] M. Baggott,et al. Abnormal visual experiences in individuals with histories of hallucinogen use: a Web-based questionnaire. , 2011, Drug and alcohol dependence.
[37] D. Nutt,et al. Decreased mental time travel to the past correlates with default-mode network disintegration under lysergic acid diethylamide , 2016, Journal of psychopharmacology.
[38] M. Liechti,et al. Receptor interaction profiles of novel N-2-methoxybenzyl (NBOMe) derivatives of 2,5-dimethoxy-substituted phenethylamines (2C drugs) , 2015, Neuropharmacology.
[39] M. Liechti,et al. Pharmacokinetic and pharmacodynamic effects of methylphenidate and MDMA administered alone or in combination. , 2014, The international journal of neuropsychopharmacology.
[40] S. Borgwardt,et al. Acute effects of LSD on amygdala activity during processing of fearful stimuli in healthy subjects , 2017, Translational Psychiatry.
[41] David E. Nichols,et al. Psychedelics , 2016, Pharmacological Reviews.
[42] M. Liechti,et al. Pharmacokinetics and Concentration-Effect Relationship of Oral LSD in Humans , 2015, The international journal of neuropsychopharmacology.
[43] T. Passie,et al. LSD-assisted psychotherapy for anxiety associated with a life-threatening disease: A qualitative study of acute and sustained subjective effects , 2015, Journal of psychopharmacology.
[44] M. Liechti,et al. Acute Effects of Lysergic Acid Diethylamide on Circulating Steroid Levels in Healthy Subjects , 2016, Journal of neuroendocrinology.
[45] Matthew W. Johnson,et al. Classic psychedelic use is associated with reduced psychological distress and suicidality in the United States adult population , 2015, Journal of psychopharmacology.
[46] Peter J Hellyer,et al. The entropic brain: a theory of conscious states informed by neuroimaging research with psychedelic drugs , 2014, Front. Hum. Neurosci..
[47] S. Unger,et al. The experimental use of psychedelic (LSD) psychotherapy. , 1970, JAMA.
[48] D. Nutt. Psilocybin for anxiety and depression in cancer care? Lessons from the past and prospects for the future , 2016, Journal of psychopharmacology.
[49] M. Geyer,et al. LSD but not lisuride disrupts prepulse inhibition in rats by activating the 5-HT2A receptor , 2009, Psychopharmacology.
[50] Matthew W. Johnson,et al. Psilocybin occasioned mystical-type experiences: immediate and persisting dose-related effects , 2011, Psychopharmacology.
[51] S. Borgwardt,et al. LSD Acutely Impairs Fear Recognition and Enhances Emotional Empathy and Sociality , 2016, Neuropsychopharmacology.
[52] M. Liechti,et al. Development and validation of an ultra-fast and sensitive microflow liquid chromatography-tandem mass spectrometry (MFLC-MS/MS) method for quantification of LSD and its metabolites in plasma and application to a controlled LSD administration study in humans. , 2017, Drug testing and analysis.
[53] Franz X Vollenweider,et al. Serotonin research: contributions to understanding psychoses. , 2008, Trends in pharmacological sciences.
[54] D. Nutt,et al. LSD enhances the emotional response to music , 2015, Psychopharmacology.
[55] F. Vollenweider,et al. Psilocybin Biases Facial Recognition, Goal-Directed Behavior, and Mood State Toward Positive Relative to Negative Emotions Through Different Serotonergic Subreceptors , 2012, Biological Psychiatry.
[56] F. Vollenweider,et al. Dreamlike effects of LSD on waking imagery in humans depend on serotonin 2A receptor activation , 2017, Psychopharmacology.
[57] J. Riba,et al. Personality, Psychopathology, Life Attitudes and Neuropsychological Performance among Ritual Users of Ayahuasca: A Longitudinal Study , 2012, PloS one.
[58] E. Seifritz,et al. Psilocybin-induced spiritual experiences and insightfulness are associated with synchronization of neuronal oscillations , 2015, Psychopharmacology.
[59] R. Kellner,et al. Dose-response study of N,N-dimethyltryptamine in humans. II. Subjective effects and preliminary results of a new rating scale. , 1994, Archives of general psychiatry.
[60] M. Liechti,et al. Acute Effects of 3,4-Methylenedioxymethamphetamine and Methylphenidate on Circulating Steroid Levels in Healthy Subjects , 2014, Neuroendocrinology.
[61] L. Hollister,et al. Mescaline, lysergic acid diethylamide and psilocybin comparison of clinical syndromes, effects on color perception and biochemical measures. , 1962, Comprehensive psychiatry.
[62] R. Griffiths,et al. Human hallucinogen research: guidelines for safety , 2008, Journal of psychopharmacology.
[63] James Rucker,et al. Psilocybin with psychological support for treatment-resistant depression: an open-label feasibility study. , 2016, The lancet. Psychiatry.
[64] D. Nutt,et al. A placebo-controlled investigation of synaesthesia-like experiences under LSD , 2016, Neuropsychologia.
[65] M. Liechti,et al. Receptor interaction profiles of novel psychoactive tryptamines compared with classic hallucinogens , 2016, European Neuropsychopharmacology.
[66] M. Liechti,et al. Development and validation of a rapid turboflow LC-MS/MS method for the quantification of LSD and 2-oxo-3-hydroxy LSD in serum and urine samples of emergency toxicological cases , 2015, Analytical and Bioanalytical Chemistry.
[67] Richard G. Wise,et al. Neural correlates of the psychedelic state as determined by fMRI studies with psilocybin , 2012, Proceedings of the National Academy of Sciences.
[68] Matthew W. Johnson,et al. Psilocybin-occasioned mystical experiences in the treatment of tobacco addiction. , 2015, Current drug abuse reviews.
[69] F. Vollenweider,et al. Acute Effects of Lysergic Acid Diethylamide in Healthy Subjects , 2015, Biological Psychiatry.
[70] K. Heekeren,et al. Psychological Effects of (S)-Ketamine and N,N-Dimethyltryptamine (DMT): A Double-Blind, Cross-Over Study in Healthy Volunteers , 2005, Pharmacopsychiatry.
[71] T. Passie,et al. Safety and Efficacy of Lysergic Acid Diethylamide-Assisted Psychotherapy for Anxiety Associated With Life-threatening Diseases , 2014, The Journal of nervous and mental disease.
[72] F. Vollenweider,et al. Phenomenology, Structure, and Dynamic of Psychedelic States. , 2016, Current topics in behavioral neurosciences.
[73] Robert Leech,et al. The effects of psilocybin and MDMA on between-network resting state functional connectivity in healthy volunteers , 2014, Front. Hum. Neurosci..
[74] D. Nutt,et al. The paradoxical psychological effects of lysergic acid diethylamide (LSD) , 2016, Psychological Medicine.
[75] M. Liechti,et al. Pharmacokinetics and Pharmacodynamics of Lysergic Acid Diethylamide in Healthy Subjects , 2017, Clinical Pharmacokinetics.
[76] F. Vollenweider,et al. Psilocybin-Induced Decrease in Amygdala Reactivity Correlates with Enhanced Positive Mood in Healthy Volunteers , 2015, Biological Psychiatry.
[77] B. Schmidt,et al. Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: a randomized controlled trial , 2016, Journal of psychopharmacology.
[78] Felix Hasler,et al. Acute, subacute and long-term subjective effects of psilocybin in healthy humans: a pooled analysis of experimental studies , 2011, Journal of psychopharmacology.
[79] Matthew W. Johnson,et al. Pilot study of the 5-HT2AR agonist psilocybin in the treatment of tobacco addiction , 2014, Journal of psychopharmacology.
[80] M. Liechti,et al. Alterations of consciousness and mystical-type experiences after acute LSD in humans , 2016, Psychopharmacology.
[81] J. Halpern,et al. A Review of Hallucinogen Persisting Perception Disorder (HPPD) and an Exploratory Study of Subjects Claiming Symptoms of HPPD. , 2018, Current topics in behavioral neurosciences.
[82] A. Feilding,et al. LSD enhances suggestibility in healthy volunteers , 2014, Psychopharmacology.
[83] J. Riba,et al. Antidepressive, anxiolytic, and antiaddictive effects of ayahuasca, psilocybin and lysergic acid diethylamide (LSD): a systematic review of clinical trials published in the last 25 years , 2016, Therapeutic advances in psychopharmacology.
[84] D. Marona-Lewicka,et al. Further evidence that the delayed temporal dopaminergic effects of LSD are mediated by a mechanism different than the first temporal phase of action , 2007, Pharmacology Biochemistry and Behavior.
[85] S. Borgwardt,et al. Increased thalamic resting‐state connectivity as a core driver of LSD‐induced hallucinations , 2017, Acta psychiatrica Scandinavica.